UNITED STATES INTERNATIONAL TRADE COMMISSION
Washington, D.C.

In the Matter of **CERTAIN SELECTIVE THYROID HORMONE RECEPTOR-BETA AGONISTS, PROCESSES FOR MANUFACTURING OR RELATING TO SAME, AND PRODUCTS CONTAINING SAME**	**Investigation No. 337-TA-1352**

NOTICE OF A COMMISSION DECISION TO EXTEND THE DEADLINE FOR DETERMINING WHETHER TO REVIEW A FINAL INITIAL DETERMINATION FINDING A VIOLATION OF SECTION 337

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission (the "Commission") has determined to extend the deadline for determining whether to review a final initial determination ("FID") of the presiding Chief Administrative Law Judge ("Chief ALJ") finding a violation of section 337 until February 12, 2025.

FOR FURTHER INFORMATION CONTACT: Houda Morad, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 708-4716. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission's electronic docket system ("EDIS") at https://edis.usitc.gov. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its Internet server at https://www.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal, telephone (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on February 9, 2023, based on a complaint, as supplemented, filed on behalf of Viking Therapeutics, Inc. of San Diego, California ("Complainant"). *See* 88 FR 8455-57 (Feb. 9, 2023). The complaint alleges a violation of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, by way of the importation into the United States or in the sale of certain selective thyroid hormone receptor-beta agonists, processes for manufacturing or relating to same, and products containing same by reason of misappropriation of trade secrets, the threat or effect of which is to destroy or substantially injure a domestic industry or prevent the establishment of a domestic industry. *Id*. at 8455-56. The notice of investigation named the following as respondents: Ascletis Pharma Inc. of Hangzhou, Zhejiang Province, China; Ascletis Pharmaceuticals Co. Ltd. of Shaoxing, Zhejiang Province, China; Ascletis Bioscience Co., Ltd.

of Hangzhou, Zhejiang Province, China; Gannex Pharma Co., Ltd. of Shanghai, China; and Jinzi Jason Wu of Seattle, Washington (collectively, "Respondents"). *Id.* at 8456. The Office of Unfair Import Investigation ("OUII") is also participating in this investigation. *Id.*

On September 22, 2023, the Commission granted a motion to intervene filed by Foster, Murphy, Altman & Nickel, PC for the "limited purpose of defending Foster Murphy and its attorneys' interests in response to Complainant Viking Therapeutics, Inc.'s Omnibus Motion for Sanctions." Order No. 37 (Aug. 28, 2023), *unreviewed by* Comm'n Notice (Sept. 22, 2023).

On October 3, 2024, the Chief ALJ issued the FID finding a violation of section 337. The FID includes a recommended determination ("RD") which recommends, should the Commission find a violation of section 337, that the Commission issue: (1) a seven-year LEO against certain selective thyroid hormone receptor-beta agonists, processes for manufacturing or relating to same, and products containing same that are imported by or on behalf of Respondents; and (2) a CDO against each of the Respondents. The RD also recommends that the Commission impose a 100 percent bond against accused articles imported during the period of Presidential review.

On November 8, 2024, Respondents, Rimon PC (Respondents' former counsel), and OUII petitioned for Commission review the FID. On the same day, Complainant filed a contingent petition for review of the FID. On November 27, 2024, the parties filed responses to the petitions.

On November 4, 2024, Complainant filed a statement on the public interest pursuant to Commission Rule 210.50 (19 CFR 210.50). The Commission did not receive any submissions from the public in response to its post-RD Federal Register notice. *See* 89 FR 82256-57 (Oct. 10, 2024).

The Commission has determined to extend the deadline for determining whether to review the FID until February 12, 2025.

The Commission's vote for this determination took place on January 30, 2025.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR Part 210).

By order of the Commission.



Lisa R. Barton
Secretary to the Commission

Issued: January 30, 2025